

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	10
-------	---	----	----

Complete if Known	
Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5116964	05/26/1992	Capon et al.	
		US- 5284935	02/08/1994	Clark et al.	
		US- 5420244	05/30/1995	Rudolph et al.	
		US- 5574205	11/12/1996	Kucherlapati et al.	
		US- 5635363	06/03/1997	Altman et al.	
		US- 5652342	07/29/1997	Zimmerman et al.	
		US- 5679641	10/21/1997	Melief et al.	
		US- 5820866	10/13/1998	Kappler et al.	
		US- 5869270	2/09/1999	Rhode et al.	
		US- 6011146	01/04/2000	Motiez et al.	
		US- 6015884	01/18/2000	Schneck et al.	
		US- 5723309	03/03/1998	Bonneville et al.	
		US- 5583031	12/10/1996	Stern et al.	
		US-6,140,113	10-31-2000	Schneck et al.	
		US-6,269,411	07-31-2001	Reasoner	
		US-6,448,071	9-10-2002	Schneck et al.	
		US-6,458,354	10-1-2002	Schneck et al.	
		US 2002/0119121	8-29-2002	Vitiello et al.	
		US 2003/0077248	4-24-2003	Moriarty et al.	
		2002/0006903	1-17-2002	Schneck et al.	
		US- 6,787,154	09-07-2004	Albani	
		Serial No. 09/642,660		Schneck et al.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

**\*EXAMINER:** Initial copy if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes and USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **2** of **10**

### Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP0352761	07/1989	Behringwerke		
		WO 93/10220	05/1993	Anergen		
		WO 93/17095	09/1993	Scripps		
		WO 93/24525	12/1993	Rijksuniversiteit Leiden; Seed Capital Investment		
		WO 94/19473 A	09/1994	Somatogen		
		WO 94/24290	10/1994	British Biotechnology Ltd.		
		WO 94/26903	11/1994	Rijksuniversiteit Leiden; Seed Capital Investment		
		WO 94/28871	12/1994	Endocon		
		WO 96/04314	02/1996	Dade International Inc.		
		WO 96/20215	07/1996	Laboratoires OM S.A.		
		WO 97/44667	11/1997	Institut Pasteur		
		WO 98/03552	01/1998	Children's Hospital Medical Center		
		WO 98/06749	02/1998	Harvard College		
		WO 98/10284	03/1998	Ortho Pharmaceutical Corp.		
		WO 99/09064	02/1999	Mount Sinai School of Medicine		
		WO 99/42597	08/1999	Harvard College		
		WO 99/50637	10/1999	Ludwig Institute		
		WO 99/64597	12/1999	USA		
		WO 01/94944	12/13/2001	Memorial Sloan-Kettering		
		WO 00/40968	07-13-2000	Unilever		
		WO 01/80833	11/01/2001	Albani		
		WO 02/065992	08/29/2002	Ortho-McNeil		
		WO 03/057171	07/17/2003	University of Pennsylvania		
		WO 94/09131	04/28/1994	Harris		
Examiner Signature			Date Considered			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 10

## **Complete if Known**

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		J. Dal Porto et al. "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations" Proceedings of the National Academy of Science of the USA vol. 90, No. 14, Jul. 15, 1993 pp. 6671-6675.	
		T. Johansen et al., "Potent inhibition of alloreactive T cells by nanomolar concentrations of a divalent soluble class I MHC molecule" The Journal of Immunology, vol. 150, No. 8, part 2, Apr. 15, 1993, p. 83A.	
		C. Gregoire et al. "Engineered secreted T-cell receptor alpha-beta heterodimers" Proceedings of the National Academy of Sciences of the USA vol. 88, No. 18, Sep. 15, 1991, pp. 8077-8081.	
		D. Eilat et al. "Secretion of a soluble, chimeric gamma-delta T-cell receptor-immunoglobulin heterodimer" Proceedings of the National Academy of Sciences of the USA, vol. 89, No. 15, Aug. 1, 1992, pp. 6871-6875.	
		S. Weber et al. "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor" Nature, vol. 356, No. 6372, Apr. 30, 1992, pp. 792-796.	
		H-C Chang et al. "A general method for facilitating heterodimeric pairing between two proteins: Application to expression of alpha and beta T-cell receptor extracellular segments" Proceedings of the National Academy of Sciences of the USA, vol. 91, Nov. 1994, pp. 11408-11412.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 10

## Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		S. O'Herrin et al. "Expression and analysis of soluble MHC- and TcR-immunoglobulin super dimers" The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996 p. A1473.	
		J. Schneck et al. "Specific inhibition of graft rejection by soluble MHC superdimers" The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996, p. A1473.	
		M. Lebowitz et al. "Specificity of soluble 2C TcR/Ig superdimers for peptide/MHC complexes" The FASEB Journal, vol. 10, No. 6, Apr. 30, 1996, p. A1178.	
		Kalandadze et al. "Expression of Recombinant HLA-DR2 Molecules" The Journal of Biological Chemistry, vol. 271, No. 33, Aug. 16, 1996, pp. 20156-20162.	
		Scott et al. "Role of Chain Pairing for the Production of Functional Soluble IA Major Histocompatibility complex Class II Molecules" J. Exp. Med. vol. 183, May 1996, pp. 2087-2095.	
		Gnjatic et al. "Mapping and ranking of potential cytotoxic in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules" Eur. J. Immunol. 25(6):1638-42 (Jun. 1995) (Abstract).	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 10

## **Complete if Known**

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Kozono et al., "Production of soluble MHC class II proteins with covalently bound single peptides" Nature 369(6476):151-54(May 1994).	
		Lee et al., "Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active beta 2-microglobulin domain" Eur. J. Immunol. 24(11):2633-39 (Nov. 1994) (Abstract).	
		Lepley et al., "Biochemical and Functional Characterization of Soluble Multivalent MHC L <sup>α</sup> /Fcy I and L <sup>α</sup> /Fcy Chimeric Proteins Loaded with Specific Peptides" Transplantation, 63:765-774 (Mar. 15, 1997).	
		Lone et al. "In Vitro Induction of Specific Cytotoxic T Lymphocytes Using Recombinant Single-Chain MHC Class I/Peptide Complexes" J. Immunother. 21(4):283-294 (1998).	
		Mage et al. "A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity" PNAS 89(22):10658-62 (Nov. 1992).	
		McCarty et al. "Targeting p53 for adoptive T-cell immunotherapy" Cancers Res. 58, 2601-05 (Jun. 15, 1998) (Abstract).	
		Matsui et al. Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness. Proc. Natl. Acad. Sci., USA, 91(26):12862-12866, 20 December 1994.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 10

## Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		McCarthy et al. "An HLA-A-restricted, p53 immune response from HLA transgenic p53 knockout mice" Ann Surg Oncol 1998 Jan-Feb, 5(1):93-9.	
		Montez et al. "Cells Expressing a Major Histocompatibility Complex Class I Molecule with a Single Covalently Bound Peptide are Highly Immunogenic" J. Exp. Med., 181:493-502 (Feb 1995).	
		White et al. "Soluble Class I MHC with $\beta$ -Microglobulin Covalently Linked Peptides: Specific binding to a T Cell Hybridoma" J. Immunol. 162(5):2671-2676 (Mar. 1999).	
		Zwimer et al. "Expression of a Functional Chimeric Ig-MHC Class II Protein" J. Immunol. 148(1):272-6 (Jan. 1992).	
		Nijman et al. "Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides" J. Immunother 1993 Aug; 14(2):121-6 (Abstract).	
		Vierboom et al. "Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes" J. Exp Med 1997 Aug; 186(5):695-704 (Abstract).	
		Kuwana et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987 Dec; 149(3):960-968.	
		Seimiya H et al. T cell receptor-extracellular constant regions as hetero-cross-linkers for immunoglobulin variable regions. J Biochem (Tokyo) 1993. Jun; 113(6):687-91.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/618,267
		Filing Date	July 14, 2003
		First Named Inventor	Schneck
		Art Unit	1644
		Examiner Name	M. DIBRINO
Sheet	7	of	10
		Attorney Docket Number	001107.00355

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		McIcief and Kast "T-cell immunotherapy of cancer" Res Immunol 1991 Jun.-Aug.; 14(2(5-6):425-9 (Abstract)	
		DeLeo "p53-based immunotherapy of cancer" Crit Rev Immunol 1998;18(1-2):29-35 (Abstract).	
		Bertholet et al. "Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides" Eur J Immunology 1997 Mar; 27(3):798-801 (Abstract).	
		Motiez et al. "A single-chain murine class I major transplantation antigen" Eur J Immunol 1991 Feb.; 21(2):467-71.	
		J. D. Altman et al. "Phenotypic Analysis of Antigen-Specific T Lymphocytes" Science, vol. 274, Oct. 4, 1996, pp. 94-96.	
		Casares et al. "Engineering and Characterization of a Murine MHC Class II-Immunoglobulin Chimera Expressing an Immunodominant CD4 T Viral Epitope" Protein Engineering, vol. 10, No. 11, Nov. 1997, pp. 1295-1301.	
		Jonathan P. Schneck, Immunological Investigations, 29(2), 163-169 (2000), "Monitoring Antigen-specific T cells Using MHC-Ig Dimers".	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 10

## Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Maucen C. Howard, et al., <i>Immunology Today</i> , vol. 20, 161-164, 1999, "MHC-based diagnostics and therapeutic-s-clinical applications for disease-linked genes".	
		Michael S. Lebowitz, et al., <i>Cellular Immunology</i> 192, 175-184 (1999), "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes. Biochemical Probes for Analysis and Modulation of Immune Responses".	
		Abdel Rahim A. Hamad, et al., <i>J. Exp. Med.</i> , vol. 188, No. 9, Nov. 2, 1998, pp. 1633-1640, "Protein T Cell Activation with Dimeric Peptide-Major Histocompatibility Complex Class II Ligand: The Role of CD4 Coreceptor".	
		Tim F. Greten, et al., <i>Proc. Natl. Sci. USA</i> , vol. 95, pp. 7568-7573, Jun. 1998, "Direct visualization of antigen-specific T cells. HPLV-3 Tax1-19-specific CD8 <sup>+</sup> T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients".	
		Sean M. O'Herrin, et al., "Analysis of the Expression of Peptide-Major Histocompatibility Complexes Using High Affinity Soluble Bivalent T Cell Receptors", <i>J. Exp. Med.</i> 186, pp. 1333-1345, Oct. 20, 1997.	
		Abbas et al., eds, <i>Cellular and Molecular Immunology</i> , 3d ed., pages 41-43	
		Deeths et al., "B7-1-Dependent co-stimulation results in qualitatively and quantitatively different responses by CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells", <i>European Journal of Immunology</i> , Vol. 27, No. 3, 1997, pp. 598-608.	
		OERTLI, et al., "Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4 <sup>+</sup> lymphocytes invitro", <i>Clinical and Experimental Immunology</i> , Vol. 110, No. 1, October 1997, pp. 144-149.	
		Papanicolaou et al., "Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele," <i>Blood</i> 102, 2498-2505, October 1, 2003	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 10

## Complete if Known

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Goldberg et al., "In vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)," <i>J. Immunol.</i> 170, 228-35, 2003	
		Levine et al., "Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T cells in the Absence of Exogenous Feeder Cells," <i>J. Immunol.</i> 159, 6921-30, 1997	
		Maus et al., "Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB," <i>Nature Biotechnol.</i> 20, 143-48, February 2002	
		Maus et al., "HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells," <i>Clin. Immunol.</i> 106, 16-22, 2003	
		NAKAMURA et al., "Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 8, No. 8, August 2002, pp 2742-2749.	
		OELKE et al., "Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells," <i>Nature Medicine</i> , Vol. 9, No. 5, May 2003, pp 619-624.	
		OELKE et al., "Generation and purification of CD8 <sup>+</sup> melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , May 2000, Vol. 6, No. 5, pp 1997-2005.	
		VON BERGWELT-BAILDON et al., "Human primary and memory cytotoxic T lymphocyte responses are effectively induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application," <i>Blood</i> , Vol. 99, No. 9, May 1, 2002, pp 3319-3325.	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 10

**Complete if Known**

Application Number	10/618,267
Filing Date	July 14, 2003
First Named Inventor	Schneck
Art Unit	1644
Examiner Name	M. DIBRINO
Attorney Docket Number	001107.00355

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Burgess et al. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. <i>J. Cell Bio.</i> 111:2129-2138, 1990.	
		Dubel et al., A family of vectors for surface display and production of antibodies. <i>Gene</i> 128, 97-101 (June 15, 1993).	
		Lisanti et al., "A glycosphospholipid membrane anchor acts as an apical targeting signal in polarized epithelial cells," <i>J. Cell. Biol.</i> 109, 2145-56, 1989.	
		Low, Glycosyl-phosphatidylinositol: a versatile anchor for cell surface proteins. <i>FASEB J.</i> 3, 1600-08, March 1989.	
		Pain & Suroli, Preparation of Protein A-peroxidase monoconjugate using a heterobifunctional reagent, and its use in enzyme immunoassays. <i>J. Immunol. Methods</i> 40, 219-30, 1981.	
		Deelder & de Water, A Comparative Study on the Preparation of Immunoglobulin-Galactosidase Conjugates. <i>J. Histochem. Cytochem.</i> 29, 1273-80, 1982.	
		Carlsson et al., Protein Thiolation and Reversible Protein-Protein Conjugation. <i>Biochem. J.</i> 173, 723-37, 1978.	
		Dupont et al., "Artificial Antigen-Presenting Cells Transduced with Telomerase Efficiently Expand Epitope-Specific, Human Leukocyte Antigen-Restricted Cytotoxic T Cells," <i>Cancer Res.</i> 65, 5417-27, June 15, 2005	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.